Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 19

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 19
---
 candidates and advance these product candidates, we may have greater difficulty raising capital on favorable terms,
or at all. In addition, there are many risks associated with our financial position and need for additional capital, as further described
below under the section titled “RISKS RELATED TO OUR FINANCIAL POSITION AND NEED FOR ADDITIONAL CAPITAL”.

If we are able to raise sufficient capital, we expect
to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses that we incur may
fluctuate significantly from quarter to quarter and year to year.

To become and remain profitable, we or a potential
partner must develop and eventually commercialize a product or products with significant market potential. This will require us to be
successful in a range of challenging activities, including completing all phases of clinical trials, obtaining marketing approval and
manufacturing, marketing and selling those products for which we obtain marketing approval. We or a potential partner may never succeed
in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If
we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our development efforts
will take several years and will require significant capital that will dilute the ownership interest of common stockholders. A decline
in the value of the Company could also cause stockholders to lose all or part of their investment.

Our development efforts have historically been
with product candidates in early-stage preclinical development. 

We currently do not have any products that have gained
regulatory approval and our development efforts have historically been focused on product candidates in early-stage preclinical development.
Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful
development and eventual commercialization of new product candidates. As a result, our business is substantially dependent on our ability
to successfully license or acquire new technologies and complete the development of and obtain regulatory approval for these product candidates.

If we are unsuccessful in accomplishing the numerous
and complex objectives in developing product candidates, we may not be able to successfully develop and commercialize new product candidates,
and our business will suffer.

 11 

Our short operating history may make it difficult
to evaluate the success of our business to date and to assess our future viability. 

We are an early development stage biotechnology company
formed on March 30, 2020. Our ongoing operations to date have been limited to organizing the